Cited by 44Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentNeuroendocrine Tumor Research Advances

High‐grade Pan IN presenting with localised stricture of the main pancreatic duct: A clinicopathological and molecular study of 10 cases suggests a clue for the early detection of pancreatic cancer

Yokode, Masataka, Akita, Masayuki, Fujikura, Kohei, Kim, Mi‐Ju, Morinaga, Yukiko, Yoshikawa, Seiichi, Terada, Takuro, Matsukiyo, Hiroshi +5 more·2018·Histopathology

Abstract

Aims: This study aimed to identify the pathological features of high‐grade Pan IN that presents with imaging‐detectable abnormalities. Methods and results: Ten cases of isolated, main‐duct, high‐grade Pan IN as the primary clinical presentation were identified. All patients presented with stenosis of the main pancreatic duct, with two being associated with extensive upstream duct dilatation (>5 mm in diameter). Pancreatic juice cytology suggested adenocarcinoma in all seven cases examined. In resected specimens, high‐grade Pan IN was present chiefly in the main pancreatic duct, with longitudinal extension ranging between 3 and 40 mm in length (median = 18 mm). In four cases, in which hypoechoic or hypovascular masses were observed on imaging, radiopathology correlations suggested that they represented parenchymal atrophy and subsequent fibrosis around affected ducts, but not invasive malignancy. On immunohistochemistry, the loss of p16 expression was found in five (50%), p53 overexpression in two (20%) and loss of SMAD 4 expression in none (0%). KRAS mutations were detected in nine cases, with two dominant clones being found in three by ultrasensitive droplet digital polymerase chain reaction, suggesting the genetic heterogeneity of dysplastic cells composing individual lesions. Mutant GNAS was also observed in one case. Conclusions: Isolated high‐grade Pan IN may present with pancreatic duct stenosis. Therefore, intensive investigations including pancreatic juice cytology will be required for patients with unexplained pancreatic duct stenosis. The abnormal expression of p53 and SMAD 4 is infrequent, while GNAS may be mutated in premalignant lesions mainly affecting the main pancreatic duct, similar to KRAS.

Integrity signals

Registry

Crossref · 10.1111/his.13629

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Yokode, M., Akita, M., Fujikura, K., Kim, M., Morinaga, Y., Yoshikawa, S., Terada, T., Matsukiyo, H., Tajiri, T., Abe‐Suzuki, S., Itoh, T., Hong, S., & Zen, Y.
Affiliations
  • Kobe City Medical Center West Hospital (JP)
  • Kobe University (JP)
  • Asan Medical Center (KR)
  • Nagaoka Red Cross Hospital (JP)
  • Fukui-ken Saiseikai Hospital (JP)
  • Toho University Ohashi Medical Center (JP)
  • Tokai University Hachioji Hospital (JP)
Corresponding author
  • Hong, Seung‐Mo
  • Zen, Yoh
Venue
Histopathology
Publisher
Wiley
Published
2018-05-30
Volume
73
Issue
2
Pages
247-258
ISSN
  • 0309-0167 (ISSN-L)
  • 1365-2559
OpenAlex
W2799853953
Cited by
44
References
25
Citations by year
2026: 1 · 2025: 4 · 2024: 8 · 2023: 8 · 2022: 1 · 2021: 4 · 2020: 6 · 2019: 9 · 2018: 3
FWCI
2.07
Type
journal article
Language
en
Open access
closed
Locations
  • Histopathology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science (15K08345, 18H02630)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
  • Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
Keywords
main pancreatic duct stenosis, pancreatic duct dilatation, pancreatic juice cytology, KRAS mutation, GNAS mutation, p53 overexpression, SMAD4 loss, p16 loss, pancreatic fibrosis, premalignant pancreatic lesions, genetic heterogeneity
MeSH terms
Aged, Carcinoma in Situ, Chromogranins, Constriction, Pathologic, Female, Humans, Male, Middle Aged, Mutation, Pancreatic Ducts, Pancreatic Neoplasms, Biomarkers, Tumor, Proto-Oncogene Proteins p21(ras), GTP-Binding Protein alpha Subunits, Gs, Carcinoma, Pancreatic Ductal, Early Detection of Cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review